Cancel
Nearby: Atlanta, GA 30308

Access Your Account

New to Healthgrades?

Join for free!

Or, sign in directly with Healthgrades:

Doctors and their Administrators:
Sign Up or Log In

Immunotherapy Changes the Game for Metastatic Melanoma

By

Maurie Markman, MD

Was this helpful? (14)
This content is selected and managed by the Healthgrades editorial staff and is brought to you by an advertising sponsor.
x

This content is created or selected by the Healthgrades editorial team and is funded by an advertising sponsor. The content is subject to the Healthgrades medical review process for accuracy, balance and objectivity. The content is not edited or otherwise influenced by the advertisers appearing on this page except with the possible suggestion of the broad topic area. For more information, read the HealthGrades advertising policy.

ADVERTISEMENT

Get the FREE "Fighting Cancer With Immunotherapy" email series.  You will receive six emails with EXCLUSIVE content on immunotherapy.

*

Which of the following conditions are you MOST interested in?

By clicking "Get Started" I agree to Healthgrade's privacy policy  and user agreement.
Medical Exam

Melanoma is a type of skin cancer that’s quite common—and quite treatable. In fact, in most cases, melanoma is caught early enough that we can remove the affected area with surgery; after that, the patient is considered cancer-free. That’s why it’s so important that patients talk to their doctors immediately after noticing a change in an existing mole’s shape, feel, or color. However, sometimes melanoma isn’t found right away and the cancer may invade other areas of the body, like the lymph nodes or blood. In these cases, treatment beyond surgery is required. Today, new treatment options like immunotherapy are giving some of these patients with advanced melanoma long-lasting and effective results.

Three patients who have treated cancer with immunotherapy discuss their experiences.

2016 Healthgrades Operating Company, Inc. All rights reserved. May not be reproduced or reprinted without permission from Healthgrades Operating Company, Inc. Use of this information is governed by the Healthgrades User Agreement.

In the past, metastatic melanoma patients would undergo chemotherapy and radiation to fight their cancer, suffering from difficult side effects, often without success. Over the last few decades, we have advanced tremendously in our treatment of melanoma; now, chemo is rarely used and radiation is only used in very specific situations. Instead, we turn to targeted therapies and immunotherapies, which are much easier for patients to tolerate and more effective for many people.

Melanoma: A Pioneer for Immunotherapy

Immunotherapy uses your own immune system to fight your cancer. Yes, that should be happening automatically, but we’ve discovered that cancer cells hide themselves from immune fighter cells. Cancer cells use molecules called checkpoints to trick the immune cells into thinking they’re friends, not foes. Your immune system might be working very hard, but it just won’t recognize the cancer cells as invaders, and thus won’t send an army to destroy them. However, in recent years, scientists have developed checkpoint inhibitors—a type of immunotherapy that reveals cancer cells to the immune system. And checkpoint inhibitors were first studied in melanoma patients, with positive results.

Melanoma was the first cancer treated with immunotherapies for several reasons. For a long time, we didn’t have reliable treatment for advanced melanoma. If melanoma couldn’t be removed surgically, and didn’t respond to chemo or radiation, patients didn’t have many options. Because of this, researchers worked hard to fill the void, and there were many patients interested in participating in clinical trials. First, they tried medications that stimulated the immune system, but those were only effective for about 10% of patients. Then, targeted therapies were introduced; this technique was (and is) successful for some patients, but not all. Today, for applicable patients, the U.S. Food and Drug Administration (FDA) has approved four different targeted therapies to treat melanoma, and we still typically turn to targeted therapies first before immunotherapies.

Finally, checkpoint inhibitors came into play in the last few years. Since 2011, three of these drugs have been approved by the FDA—ipilimumab (Yervoy), pembrolizumab (Keytruda), and nivolumab (Opdivo). They stop cancer cells from hiding from the immune system. These new drugs are incredibly effective and patients who respond can live long lives free from melanoma. Right now, only about 30 to 40% of patients respond to checkpoint inhibitor immunotherapies—so it doesn’t yet work for everyone. But when it works, it shows remarkable success, with fairly manageable side effects like fatigue and diarrhea. More than a third of patients treated with these immunotherapies are alive five years after starting treatment—that’s twice the number of patients alive five years after treatment with other methods. And clinical trials happening now are showing that the combination of two different checkpoint inhibitors works in 50% of patients (although side effects are harder to manage).




THIS CONTENT DOES NOT PROVIDE MEDICAL ADVICE. This content is provided for informational purposes and reflects the opinions of the author. It is not a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of a qualified healthcare professional regarding your health. If you think you may have a medical emergency, contact your doctor immediately or call 911.


Maurie Markman, MD

Maurie Markman, MD, is a nationally-renowned oncologist who serves as President of Medicine and Science at Cancer Treatment Centers of America. View his Healthgrades profile >

Was this helpful? (14)

© 2016 Healthgrades Operating Company, Inc. All rights reserved. May not be reproduced or reprinted without permission from Healthgrades Operating Company, Inc. Use of this information is governed by the Healthgrades User Agreement.

Your opinion matters!



Please fill out this short, 1-3 minute survey about Advances in Immunotherapy. Your answers are anonymous and will not be linked to you personally.

The survey will appear at the end of your visit.

Thank you!

A survey will be presented to you after you finish viewing our Advances in Immunotherapy content.

You Might Also Like

Share via Email

PREVIOUS ARTICLE:

With Immunotherapy, My Lung Cancer Is a Chronic Disease

NEXT ARTICLE:

How Immunotherapy Is Revolutionizing Lung Cancer Treatment

Up Next

How Immunotherapy Is Revolutionizing Lung Cancer Treatment